Anidula

Introduction
Anidula is an antifungal medication. It is used in the treatment of severe fungal infections. It kills the fungi that cause infections and thus provides relief. Anidula is administered as an injection by a healthcare professional. Kindly do not self administer. Do not skip any doses and finish the full course of treatment even if you feel better. Your liver function should be monitored regularly during treatment. It may lead to a few common side effects like decreased potassium levels in the blood, nausea, diarrhea, headache, and vomiting. You may also notice some injection site reactions like pain, swelling or redness. Inform your doctor if these side effects persist for a longer duration. Please consult your doctor if you are pregnant, planning to conceive or breastfeeding.

_
Uses of Anidula
Severe fungal infections
Side effects of Anidula
Common
Decreased potassium level in blood
Nausea
Diarrhea
Headache
Vomiting
Fever
Anemia (low number of red blood cells)
Insomnia (difficulty in sleeping)
Indigestion
How to use Anidula
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Anidula works
Anidula kills fungus by preventing them from making their protective covering.
What if you forget to take Anidula?
If you miss a dose of Anidula, please consult your doctor.
Quick Tips
Do not skip any doses and finish the full course of treatment even if you feel better.
Your doctor may check your liver function regularly. Inform your doctor if you develop abdominal pain, loss of appetite, darkened urine or yellowing of the eyes or skin (jaundice).
Inform your doctor if you are pregnant, planning pregnancy or breastfeeding.
Brief Description
Indication
Oesophageal candidiasis, Invasive candidiasis, Candidaemia, Candida infections (intra-abdominal abscess, pertonitis)
Administration
IV Preparation Reconstitute each 50 mg vial w/ sterile water for inj 15 mL, or each 100 mg vial w/ sterile water for inj 30 mL to provide a concentration of 3.33 mg/mL. Further dilute the reconstituted solution w/ either dextrose inj 5% or sodium chloride inj 0.9% to obtain a solution containing 0.77 mg/mL.

_
Adult Dose
Intravenous Oesophageal candidiasis Adult: Loading dose of 100 mg on day 1, then 50 mg once daily thereafter. Continue treatment for at least 14 days and for at least 7 days following resolution of symptoms. To be given by IV infusion. Max infusion rate: 1.1 mg/min. Invasive candidiasis, Candidaemia, Candida infections (intra-abdominal abscess, pertonitis) Adult: Loading dose of 200 mg on day 1, then 100 mg once daily thereafter. Continue treatment for at least 14 days after the last positive culture. To be given by IV infusion. Max infusion rate: 1.1 mg/min.

_
Renal Dose
No dosage adjustment needed.
Contraindication
Hypersensitivity to anidulafungin or other echinocandins.
Mode of Action
Anidulafungin is a semi-synthetic echinocandin antifungal. It inhibits 1, 3-beta-D-glucan synthesis, an essential component of the fungal cell walls. It has been shown to have in vitro activity against many Aspergillus spp and Candida spp.
Precaution
Patients w/ serious underlying conditions receiving multiple concomitant medications w/ anidulafungin may experience hepatic abnormalities e.g. hepatitis, hepatic dysfunction or worsening hepatic failure. Pregnancy and lactation. Lactation There are no data on presence of drug in human milk, effects on breastfed infant or on milk production; drug was found in milk of lactating rats; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from therapy or from underlying maternal condition

_
Side Effect
1-10% Candidemia treatment Diarrhea (3%) Hypokalemia (3%) Abnl LFTs (2%) Esophageal Candidiasis treatment Headache (1%) Nausea (1%) Neutropenia (1%) Rash (1%) Frequency Not Defined Possible histamine-mediated symptoms reported including rash, urticaria, flushing, pruritus, bronchospasm, dyspnea, and hypotension; infrequent when infusion rate does not exceed 1.1 mg/minute.

_
Pregnancy Category Note
Pregnancy Based on findings from animal studies, therapy can cause fetal harm when administered to a pregnant woman; there are no available human data on use in pregnant women to inform a drug-associated risk of adverse developmental outcomes Lactation There are no data on presence of drug in human milk, effects on breastfed infant or on milk production; drug was found in milk of lactating rats; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from therapy or from underlying maternal condition

_